¡@
¡@
¡@

¦b°ò¦]¤ô¥­¤W¬ã¨s¶Ý¤¤©Ê¥Õ¦å²yªº°ò¦]ªí¹FÅܤƴ£¥Üºë¯«­×·Ò½Õ±±°ò¦]ªí¹F¡]¹Ï¡^
¥´¦L¾÷ª©
¤å/«Ê²ú²ú µ¥
¡@
¡i¼z¶é¡j

§õ¥þ­s¡¯ §õ¥­¡­ ¥[ªi·ç¦ã®R•¥[¦è¨È# ²z¬d¼w•±j´Ë# «Ê²ú²ú¡­

¡¯¢Ò¢Ü¢Ï·L±Æ¦C¤¤¤ß¡A§K¬Ì¾Ç¤¤¤ß¡A¦è«n¼w§JÂÄ´µ¤j¾ÇÂåÀø¤¤¤ß
¹F©Ô´µ¡A¼w§JÂÄ´µ¦{¢¶¢´¢²¢¸¢¯

¡­¨©°ÇÂå¾Ç°|¡AÂå¾Ç¨t
¥ð´µ¹y¡A¼w§JÂÄ´µ¦{¢¶¢¶¢¯¢²¢¯

ºK­n

¦b°ò¦]¤ô¥­¤W¡A¤HÃþ©M¨ä¥¦ª«ºØ¦³µÛ¥O¤H¤£¥i«äijªº¬Û¦ü©Ê¡A³o«P¨Ï§Ú­Ì¥tÅPÁÑ®|¥h´M§ä»P¤Hªº¯S©Ê¦³Ãöªº¡A¦b°ò¦]½Õ±±¤¤°_­«­n§@¥Îªº¦]¯À¡C¶V¨Ó¶V©úÅ㪺¦w¼¢¾¯®ÄÀ³»¡©ú¤Hªº«ä·Q(ºë¯«)¯àÅãµÛ¼vÅT¨ä¹ï©ó°·±d¡B¯e¯f¡B©MÂåÃĪº¤ÏÀ³¡Cºë¯«­×·Ò©M«H¥õ¦b­ÓÅé¹ï©ó°·±d°ÝÃD©M¯e¯fªº¤ÏÀ³¤¤°_µÛ­«­nªº§@¥Î¡A¨Ã±N¼vÅT¨ì­ÓÅ骺¥Í¬¡©M©¯ºÖ¡C¦]¦¹¡A§Ú­Ì¹ï¤@¸s¶i¦æºë¯«­×·Òªº¤H¡A¦b°ò¦]¤ô¥­¤W¬ã¨s¤F¥L­Ìªº°ò¦]ªí¹Fª¬ªp¡C©M¥¿±`°·±d¤H¬Û¤ñ¡A§Ú­Ìµo²{ªk½ü¥\¾Ç­ûªº¶Ý¤¤©Ê¥Õ¦å²yªº¥\¯à¥H¤Î°ò¦]ªí¹F¦³µÛ«D±`ÅãµÛªºÅܤơC³o¨ÇÅܤƪí²{¬°¡G§]¾½©M±þ¶Ë²Óµßªº¥\¯à¼W±j¡A©M§K¬Ì¤O¦³Ãöªº°ò¦]ªí¹F¼W¥[¡A²Ó­M¦º¤`°ò¦]³QÂù¦V½Õ±±±q¦Ó¨Ï±o¥¿±`²Ó­M¦s¬¡´Á©µªøªº¦P®É¤S¥[³t¨ü¨ë¿Eªº²Ó­M­ä¹s¦º¤`¥H«Kª¢¯g¨³³t®ø°£¡A¥H¤Î²Ó­M·s³¯¥NÁªº¤U­°µ¥µ¥¡C²Ó­M·s³¯¥NÁªº¤U­°ªí²{¦bªx¯À¨Ì¿à©Êªº³J¥Õ½è­°¸Ñ¨t²Îªº¬ÛÄ~¤U½Õ±±¡A³oºØ¤U½Õ±±¥i¯à¬O©M²Ó­M¤ºªº¥NÁ²£ª«´î¤Ö¬ÛÃö¡A¦Ó«Dª½±µ½Õ±±¡C²Ó­M¦º¤`ªºÂù¦V½Õ±±¥i¯à¬O³±¶§½Õ©Mªºªí²{¡A¦]¬°ª¢¯gª¬ºA¤Uªº²Ó­M¦º¤`¥[³t¥i¯à¨Ï¾÷Åé¦b§K¬Ì¤O¼W±j®É¨S¦³°Æ§@¥Î¡Ð±J¥Dªº¦Û¶Ë¡C§Ú­Ì³oùØ´£¨Ñ¤F²Ä¤@¤âÃÒ¾Ú¡A¨ÓÃÒ©úºë¯«­×·Ò¥i¯à³q¹Lºë¯«¼h­±¤W¹ï°ò¦]²Õªº½Õ¸`¨Ó§ïÅܧK¬Ì¤O¡B²Ó­M¦º¤`©M·s³¯¥NÁ²vµ¥µ¥¡C³o¨Çµo²{»¡©ú¤F¤Hªººë¯«¹ï¾÷Å骺¦ÜÃö­«­nªº½Õ¸`§@¥Î¡A·N¨ýµÛ§Ú­Ì«æ»Ý«Ø¥ß§ó¦hªº¼Ò«¬¨Ó¬ã¨s·NÃÑ¡B»{ª¾¡B©Mºë¯«µ¥¤HÃþ¯S¦³ªº¯S©Ê©M¦æ¬°µ¥¦]¯À¹ï°ò¦]½Õ±±ªº¼vÅT¡C

¦³¦hºØ¦]¤l¦b¤HÃþ°·±d¤¤°_µÛ­«­n§@¥Î¡C³o¨Ç¦]¤l¥i¯à¦b¤ß²z¤W°_§@¥Î±q¦Ó¼vÅT§K¬Ì©M¯«¸g¤º¤Àªc¨t²Î[1,2]¡C2000¦~6¤ë27¡B28¤é¡A¦b¬ü°ê°ê¥ß°·±d¬ã¨s©Ò(NIH)ªºNatcher·|ij¤¤¤ß¥l¶}¤F¥Ñ¸Ó©Ò¥D¿ìªºÃD¬°¡§´Â¦V°ª¼h¤ÀªR¡¨ªº¬ã°Q·|¡C·|ijªº¥DÃD´N¬O¦p¦ó¥[±j¬ã¨sªÀ·|©M¤å¤Æ¹ï°·±dªº¼vÅT¡C¬°¨Ï¤j®a§ó¦n¦a»{ÃѨì¦b°·±d½Õ¬ã¤¤ªÀ·|¡B¦æ¬°©M¥Íª«¼h­±¤W¤ÀªR¬ã¨sªº¬Û¤¬¨Ì¿à©Ê¡A·|ij±j½Õ¤FªÀ·|¤å¤Æ¦]¯À¹ï°·±d©M¯e¯fªº¼vÅT¡C·|¤W¡AªÀ·|¾Ç®a´£¥X¤F§@¬°³æ¤¸¤ÀªRªºªÀ·|©M¤å¤ÆÅé¨t¡A»{¬°À³¸Ó¦b¥]¬A©v±Ð©Mºë¯«¬¡°Êµ¥ªÀ·|©M¤H»ÚÃö«Y¦p¦ó¼vÅT°·±d³o¤@¤è¦V¤W¡A¶i¦æ§ó¬°¼sªxªº¬ã¨s [3]¡Cªø´Á¥H¨Ó¡A¤H­Ì¤@ª½¦b²q´ú¤Hªº«ä·Q·|ÅãµÛ½Õ±±¤HÅé¡C¤£¹L¡A¤Hªº«ä·Q¦p¦ó¦b¤À¤l©M²Ó­M¤ô¥­¤W¨ãÅé¦a½Õ±±°ò¦]ªí¹F¡A¤´¬O§Ú­Ì»Ý­n¬ã¨sªº½ÒÃD¡C

¤HÃþ°·±dªºÃöÁä¦]¯À¢w¤H©Ê¡G³£¦b©óºë¯«·NÃѤ¤

¬ì¾Ç®a¦b25¦~«e³ø¾É»¡¡A¤£¦Pª«ºØ¶¡ªº®t²§¥i¯à¥u¬O·½©ó°ò¦]ªí¹F¼Æ¶qªº®t²§¡A¦Ó«D°ò¦]ªº¤@¯Åµ²ºc¤£¦P[4]¡C©Ò¦³­÷¨Å°Êª«ªº°ò¦]®w¬O¦p¦¹ªº¬Û¦ü¥H¦Ü©ó«ÜÃø²z¸Ñ¬°¦ó¬Û¦üªº°ò¦]ª«½è·|²£¥Í¦p¦¹²³¦hªº¤£¦P¥Íª«[5]¡C¶ÂµVµV©M¤HÃþ´N¨ã¦³98.7%ªº¬Û¦P°ò¦]ª«½è¡A·íµM¦b§ÎºA©M»{ª¾¯à¤O¤W¡A¤GªÌ¨ã¦³·¥¬°ÅãµÛªº®t²§ [6]¡CEnandµ¥¤H±À´ú°ò¦]ªí¹F¤è¦¡ªº®t²§©Ê¥i¯à³y¦¨¤Fª«ºØ¤§¶¡ªº®t²§¡C¥L­Ìµo²{¤jµVµV©M¤H¥u¦b¸£³¡ªº¬Y¨Ç°ò¦]Âà¿ý¤è¦¡¤W¦³®t²§¡A¥B¤H¸£ªº¬Y¨Ç°ò¦]¬¡©Ê¼W±j[6]¡C¦³¨Ç¬ì¾Ç®a»{¬°À³¸Ó¥Î¤@­Ó¡§Âà(¤HÃþ¯S²§©Ê)°ò¦]¤p¹«¼Ò«¬¡¨¨Ó¶i¤@¨B¬ã¨s¬O§_¬Y¨Ç¤HÃþ¯S²§©Ê°ò¦]¯à§â¤p¹«Åܱo§ó¹³¤H¡C·íµM¡A¤]¦³ªº¬ì¾Ç®aı±o³o¼Ëªº¡§Å]³N¡¨°ò¦]®Ú¥»´N¤£¦s¦b¡C

¨º»ò¶W¶V¤@ºû°ò¦]®w¥H¥~ªº¡§Å]³N¡¨¦]¯À¬O¤°»ò©O¡H¦pªG¤£¦P°Êª«ªº°ò¦]¦p¦¹Ãþ¦ü¡A¤]³\¤H»P¨ä¥Lª«ºØªº®t²§©Ê¦b©ó¤Hªº°ò¦]¨ü°ª¯Å«äºû½Õ±±ªºÅܤƳy¦¨ªº¡A¦Ó³oºØÅܤƵo¥Íªº®É¶¡¡A³¡¦ì¡A©M±j«×¥i¯à·|°_µÛ¨M©w©Êªº§@¥Î¡C¤H©M¤jµVµVªº¤j¸£¦b°ò¦]¬¡©Ê¤Wªº®t²§»¡©ú¤F¤HÃþªº¯S²§©Ê¥i¯à¥Ñ¤HÃþ¯S¦³ªººë¯«¬¡°Ê¥D®_¡A°ò¦]®wªº¤@¯Åµ²ºc¤£¥i¯à¬O°ß¤@ªº¦]¯À¡C¤HÃþ©M¨ä¥¦¥Íª«ªº¦b¯e¯f©M°·±d¤Wªº¥¨¤j®t²§·t¥Ü§Ú­ÌªÖ©wÁÙ¦³¨ä¥¦¦]¯À¡C¹ï©óª«²z©M¯f²z­ì¦]³y¦¨ªº°ò¦]½Õ±±¡A§Ú­Ì¤w¦³¤F¬Û·í¦hªº¤F¸Ñ¡A¦ý¬Oºë¯«¦p¦ó½Õ±±°ò¦]ªí¹F¡A­þ¨Ç°ò¦]¯à¨ü«ä·Q¬¡°Êªº¼vÅT¡A¥¦­Ì¤S¬O¦p¦ó¥h¶i¤@¤£½Õ±±¨º¨Ç¨üª«²z©M¯f²z¨ë¿E½Õ±±ªº°ò¦]¡A¹ï©ó³o¨Ç°ÝÃD§Ú­Ì«o¬Oª¾¤§¬Æ¤Ö¡C

¡§¦w¼¢¾¯/¤Ï¦w¼¢¾¯¡¨®ÄÀ³ªº±Ò¥Ü

¡§¦w¼¢¾¯(Placebo, ·½©ó©Ô¤B¤å¡§§Ú·|°ª¿³¡¨)®ÄÀ³¡¨¬O«ü¯f¤H¦b¨Ï¥ÎµLÃĩʤù¾¯(¦p¿}¤ù)«á²£¥Íªº¨}¦n·Pı¡C³oºØ²{¶H¦bÂå¾Ç¬ÉÀH³B¥i¨£¡A¥H­P«Ü¤Ö¦³Âå¥Í¹ï¨ä´£¥X¬D¾Ô[7-11]¡C¦Ó¡§¤Ï¦w¼¢¾¯(Nocebo,·½©ó©Ô¤B¤å¡§§Ú·|¨ü¶Ë¡¨)®ÄÀ³¡¨«ê«ê¬Û¤Ï¡A¥¦Åý§Ú­Ì¬Ý¨ì®ø·¥ªº·Qªk·|¹ï¡§³Q¸Õ¡¨²£¥Í¤£¨}¼vÅT [12-15]¡C¡§¦w¼¢¾¯®ÄÀ³©M¤Ï¦w¼¢¾¯®ÄÀ³¡¨»¡©ú¡A¯f¤Hªº«ä·Q(ºë¯«)¦b¨ä¹ï©ó¯e¯f©MÃĪ«ªvÀøªº¤ÏÀ³¤¤·|§êºt­«­nªº¨¤¦â¡C

ÁöµM«Ü¤Ö¦³¤H¹ï¦w¼¢¾¯®ÄÀ³´£¥X²§Ä³[16]¡A³ÌªñPetrovicµ¥¤H©ú½T´£¥X¡A¤£ºÞ¬O¦w¼¢¾¯ÁÙ¬O¤îµh¤ù³£¯à¦b¤j¸£´I¦³¡§¾~¤ù·P¨üÅ顨ªº¦P¤@°Ï°ì¥[±j¦å²G¬y°Ê[17]¡C¦bÀH«áªº¤@­Ó©¬ª÷´Ë¤óºî¦X¯gªºÁ{§É¯f¨Ò©M¤j¦h¼Æ§Ü§íÆ{¾¯¸ÕÅ礤¡Aµo²{¦w¼¢¾¯¤£¶È½w¸Ñ¤F¯fª¬ÁÙ§ïÅܤF¤j¸£ªº¤Æ¾Ç¤ÏÀ³[18-20]¡C¬ì¬ã¤H­ûµo²{¡A»P20¦~«e¬Û¤ñ¡A§ó¦hªº¯f¤H¦b¨Ï¥Î¦w¼¢¾¯«á¯f±¡¦³¦nÂà¡C³o»¡©ú²{¥N¥Í¬¡ªººò±i©MÀô¹ÒªºÀ£¤O¥i¯à¤Þ°_¤F§ó¦hªº»P¤ß²z¦³Ãöªº¯e¯f¡CTorrey©M Miller³Õ¤h¦b¥L­ÌªºµÛ§@¡m¬Ý¤£¨£ªº½E¬Ì¡G±q1750¦~¦Ü¤µºë¯«¯fªº¼Wªø¡n¤¤Á`µ²¨ì¡A¡§ªñ´X¤Q¦~¨Ó¡A¦Ü¤Ö¦b¤@¨Ç¤u·~°ê®a¡A½TÆwªºÃÒ¾Úªí©ú¥Ñªq³à©M±¡ºü§C¸¨¤Þ°_ªº¤HÃþ¯e¯f¦³½¯©µªºÁͶաA¬Æ¦Ü¬O³ÌÄY­«ªººë¯«¯¿¶Ã--ºë¯«¤Àµõ¯g¡¨[21]¡C¦b¤@¶µ°w¹ï2001¦~9¤ë11¤é¤§«á¤ß²zÀ£¤O¤ÏÀ³ªº½Õ¬d¤¤¡A ¡§¢¸¡þ¢°¢°«á®ÄÀ³¡¨¶i¤@¨BÃÒ¹ê¤F³o¼Ë¤@ºØÁͶաG§Y¨Ï»·Â÷¥X¨Æ¦aÂIªº¤H¤]ªí²{¦³¹ê½è¤Wªººë¯«À£¤O¯gª¬[22]¡C¦í¦b¡§Âù¶ð¡¨ªþªñªºÀ³µªªÌ¤¤¡A¦³20%ªº¤Hªí²{¥X¡§­«¤j³Ð¶Ë«á¿ò¯g¡¨(©ÎºÙ¡G³Ð¶Ë«áÀ³¿E»Ùê¡APTSD)23¡C¦b¥t¤@¶µ°w¹ï988¦W°Ò«¢¹y©~¥Áªº¬ã¨s¤¤µo²{¡A©â·Ï¡B³Ü°s©M§l¤j³Âªº¶q³£¦³ÅãµÛ¼W¥[¡A¦Ó³o¥i¯à»P¤£¦Pªº¤ß²zª¬ªp¦³Ãö[24]¡C¾Ú±Ð¨|§½ªº¬ã¨sªí©ú¡A¦b¤@¶µ°w¹ï110¸U¤½¥ß¾Ç®Õ¾Ç¥Íªº½Õ¬d¤¤¡A¬ù¦³75,000¦W¨àµ£ªí²{¥X¤»ºØ¥H¤WªºPTSD¯gª¬¡A¦Ó³o¨¬¥H³Q¶EÂ_¬°ºë¯«¯¿¶Ã[25,26]¡C

«Ü©úÅã¡A¦w¼¢¾¯ªºªv¯f®ÄªG¬O¥Ñ©ó¤Hªº´Á±æ©M«H©À¯à¼vÅT¥Í²z¤ÏÀ³[27]¡C¥t¥~¡A¦w¼¢¾¯®ÄÀ³ªñ¦~ªº¼W¥[¤]»¡©ú¤F²{¥NªÀ·|¤HÃþªººî¦X¯e¯f©M¤ß²zÀ£¤Oªº¼W¥[¥i¯à»P¤HÃþ¯S¦³ªº¤ß²z¦]¯À¦³Ãö¡C³o´N¬O»¡¤HÃþªº¯e¯f¤£¶È¶È·½©ó²³æªº¯f²z¡B¥Í²z¡Bª«²z¨ë¿E¥H¤Î°ò¦]¯Ê³´¡C¦]¦¹¡A¥Ø«e¥H°Êª«¼Ò«¬¬°°ò¦ªº°w¹ï¹v°ò¦]ªº¬ã¨s´N§¹¥þ¤£À³¸Ó¦¨¬°¬ã¨s¤HÃþ¯S¦³¯e¯fªº¯f·½¾Ç¡B¯f²z¾Ç©M¤ß²z¾Çªº°ß¤@°ò¦¡C

¦b°ò¦]¤ô¥­¤W´ú©w»P°·±dªí«¬¦³Ãöªº°ò¦]ªí¹Fª¬ªp

©Ò¦³ªº¥Íª«¤ÑµM´NÀ³¸Ó¦³¤@­Ó§¹¾ãªº¡A¦Û§Ú½Õ±±ªº°·±dªº¥Í¬¡¡C¤£¨}ªº°·±dª¬ªp¤£¬O¤@ºØ¦ÛµMª¬ºA¡C¤@¯ë»¡¨Ó¡A¥Íª«±q¥»½è¤W¬O¤£¸Ó¥Í¯fªº¡A¦p¦P©I§l¡B®ø¤Æ¡B¤Àªc©M¥Í´Þ§@¥Î¡A¥Íª«Å餺´N¨ã³Æ²Õ´ªº¦Û·U¹Lµ{¡C°·±d¬O¤@ºØ¦ÛµMª¬ºA¡A¦]¬°¥¦¬O©M¿Óªº¡B¥­¿Åªº¡C©Ò¥H¡A½T©w¦b°·±dªº¤H¸s¤¤°ò¦]¦p¦ó¨ü¤ß²z©Mºë¯«ªº½Õ±±«D±`­«­n¡A¦]¬°¨º¨Ç¥Íª«Åé¨t¥i¯à¨ã¦³§ó°ªºûªº«H®§¡A±q¦Ó«O«ù°·±d©M§Ü¯e¯f¯à¤O¼W±j¡C

°ò¦]ªí¹Fªº½Õ±±¬O¥Íª«¾Ç²{¶Hªº¤@­Ó­«­n¤è­±¡C¦b¹ïÀô¹Ò±ø¥óªº¤ÏÀ³¡A¦h²Ó­M²Õ´ªºµo®i¡A§ÎºAªºÅܤơA©M¯f²zªº§ïÅܵ¥¤è­±ÁöµM³£¦³¼sªxªº¬ã¨s¡A¦p¦ó½T©w°ò¦]ªº¯f²z¾ÇÅܤƤ´¹ï¬ã¨s¤H­û¬O¤@­Ó¥¨¤jªº¬D¾Ô¡C¦b¡§¯e¯f¡¨ªº°ò¦¤W¨Ó½T©wµo¯f¦³Ãöªº°ò¦]Åܤƥi¯à¦³¤£¤Ö°ÝÃD¡A¦]¬°¤@¨Ç¦³§Q©ó¾÷Å骺¤W½Õ±±©Î¤U½Õ±±¥i¯à³Q»{¬°¬O¦³®`ªº¡A¤Ï¤§¥çµM¡C°Êª«¼Ò«¬¬O¤@­Ó«Ü¦nªº¬ã¨s¨t²Î¡CµM¦Ó¡A»P¤H©Ê¦³Ãöªº½ÆÂø¦]¯À«o§¹¥þ¤£¯à¥Î°Êª«¨Ó¬ã¨s¡A¦]¬°¤Hªº»{ª¾¡B¦æ¬°¡B©M«äºû¥Ã»·¤£¥i¯à¦³°Êª«¼Ò«¬¡A¨ä¤¤¤]¥]¬A¹ï³Ì°ª¯ÅªºÆFªøÃþ°Êª«¶ÂµVµVªº¬ã¨s¡C¦¹¥~¡A¥Ø«e©|µL¹ï©ó¤Hªº¤ß²z©Mºë¯«¯S½èªº¬ì¾Ç´ú¶q³æ¦ì¡C

³Ì±`¨£ªº¯e¯f¤Ï¦Ó³ÌÃø¬ã¨s¡C¤ßŦ¯f¡BÀù¯g¡B¿}§¿¯f©Mºë¯«¯fµ¥µ¥¡A©Ò¦³³o¨Ç³£³Q»{¬°¬O¡§½ÆÂøªº¡¨©M¡§¦h¦]¯À¡¨¯e¯f¡A¦]¬°¥¦­Ì¤£¬O¥Ñ³æ­Ó°ò¦]ªºÅܲ§©M³æ¤@¥~¬É±ø¥ó©Ò³y¦¨ªº¡C¡§­Ô¿ï°ò¦]¹Gªñªk¡¨¤]¨ü¨ì§åµû¡A¦]¬°«Ü¦h¹êÅçµ²ªG¨S¦³­«ÂЩʡA¨Ã¥B¥¦µLªk¥]²[©Ò¦³ªº¦¨¦]°ò¦]©M°ò¦]ªº¦hºA²{¶H[28]¡C¨º¨Çºî¦X¯e¯f¹ê»Ú¤W²£¥Í©ó«Ü¦h°ò¦]ªºÁp¦X§@¥Î¡A¥H¤ÎÀô¹Ò¦]¯À¤Î«_ÀI¦æ¬°µ¥[29-32]¡C¦bªñ´Á¡m¬ì¾Ç¡nÂø»x¤W¡A¦³¦h½g¤å³¹ÄÄ­z¤F¬ì¬ã¤H­û¦b¬ã¨sºî¦X¯e¯f®É¹J¨ìªº§xÃø[29,33-35]¡C­n·Q½T©w¯S©wªº°ò¦]¾É­P¤Fºî¦X¯e¯f¡A´N¹³¤j®ü¼´°w¤@¼ËÃø¡C¦]¬°§Y«K¯à§ä¨ì¡A³o¨Ç°ò¦]©¹©¹¥u¹ï³o¨Ç½ÆÂø©Ê¯e¯fªº§Î¦¨°_·L¤pªº§@¥Î¡C¦P®É¡A³o¨Ç§@¥Îªº¤j¤p¤S¨ü¤£¬ÛÃö°ò¦]©MÀô¹Ò¦]¯À¡A¥H¤Î¤Hªº«ä·Q(ºë¯«)ªº¼vÅT¡C¸g±`¬O¦b¤@­Ó¸ÕÅç¤H¸s¤¤½T©wªººî¦X¯e¯fªº©ö·P°ò¦]®y¦b§Oªº¤H¸s¤¤µLªk­«ÂСC¶V¨Ó¶V¦hªº¬ã¨sµo²{¡A¹ï©ó¨º¨Çºî¦X¯e¯f¡A¶W¹L70%ªº¤¤­·¡Bª½¸zÀù¡B«a¤ß¯f©M²Ä¤G«¬(¦¨¤H«¬)¿}§¿¯f³£¥i¥H³q¹L§ïÅܥͬ¡¤è¦¡¦Ó±o¨ì¹w¨¾¡C³o»¡©ú¦Û§Ú½Õ±±¦b¹w¨¾¦¹Ãþºî¦X¯e¯f¤¤°_µÛ­«­nªº§@¥Î[30,33]¡C¬Ý¨Ó¡A¹w¨¾¤´¬O³Ì¦nªºªvÀø[36]¡A¦]¦¹§Ú­Ì«E»Ý¬ã¨s¬°¤°»ò¦³¨Ç¤H¯à«O«ù°·±d¡A¥H¤Î¥L­Ì¦p¦ó¨ã¦³¹ï¯e¯fªº©è§Ü¤O[37,38]¡C

¤H­Ì¹ï©ó¨­¤ßºò±K¬ÛÃö³o¤@²{¶H¶V¨Ó¶V·P¿³½ì¡C¦Ó¦­¥ý¡A³o¤@½ÒÃD¥¿¬O¥Ñ©ó¥¦ªº½ÆÂø©Ê¦Ó³Q¨t²Îªº¬ì¾Ç¬ã¨s±Æ¥¸¦b¥~¡C¨­¤ßÂå¾Ç(MIND/BODY MEDICINE) ¬O«Ø¥ß¦b¹L¥h25¦~¤¤2000¦h½gµoªí¦b¥Ñ±M®a¼f©wªºÂø»x¤Wªº¬ì¾Ç¬ã¨sªº°ò¦¤W[27]¡C«¢¦òÂå¾Ç°|ªºHERBERT BENSON¡A³o¦ì¡§¨­¤ßÂå¾Ç¡¨ªº¥ýÅX¦b³o¤@»â°ì¤¤§@¥X¤F¥¨¤jªº°^Äm¡C¦h¦~¨Ó¿n²Ö¤U¨ÓªºÂ×´IÃÒ¾Úªí©ú(¤ßÆF)­×·Ò©ÒÀò±oªºÅãµÛªº¥Í²z®ÄÀ³ª½±µ»P«ä·Q¤ÎÆF©Ê¦³Ãö¡C³oÃþ­×·Ò¥]¬A©v±Ð©M«D©v±Ð­×·Ò¡C¦b¦è¤èªÀ·|¡A©v±Ð­×·Ò¦û¥D¾É¦a¦ì¡A¦ÓªF¤è¤å¤Æ«h±j½Õ³q¹L¨­Åé©Mºë¯«ªº°V½m¨Ó¿E¬¡¯à¶qÅé¨t¡A¤ñ¦p·ìÏÉ¡B®ð¥\¡B¤Ó·¥¥H¤Î³Ìªñ¥X²{ªºªk½ü¥\(FLG)¡A¤SºÙªk½ü¤jªk[39-44]¡C¥¿·í·ìÏÉ¡B¥´§¤©Î¬è몺°·¨­®ÄªG¶V¨Ó¶V¦h¦a³QÃÒ¹ê¨Ã³vº¥³Q¤½²³©Ò±µ¨üªº®É­Ô¡C³o¨ÇÅãµÛ®ÄªG¦b¥Í²z¤ô¥­¤Wªº¾÷²z¨Ã¥¼³Q¤H­Ì¼sªx»{ÃÑ¡A§ó¤£¥Î»¡¦b²Ó­M©Î¤À¤l¤ô¥­¤W¥hÃÒ¹ê©M¨t²Îªº¬ã¨s¡C¥t¤@¤è­±¡A¥Íª«¬ã¨s§Þ³Nªº¤@¨Ç­«¤j¶i¨B¨Ï§Ú­Ì¥i¥H¹ï³æ­Ó²Ó­M¤º³\¦h¨ãÅ骺Åܤƶi¦æ§Ö³t©Mºë½TªºÀË´ú¡C³o¨Ç¬ì¾Ç§Þ³Nªº¶i®i¦³§Q©ó¬ã¨s³o¨Ç­×·Ò¤Þ°_ªº¨­Åé¦b²Ó­M©Î¤À¤l¤ô¥­¤WÅܤơC®Ú¾Ú1999¦~ªì¤¤°ê¬F©²ªº¤@¥÷½Õ¬d¡A¦b¤¤°ê¤j³°¦³7¤d¸U¨ì1»õ¤H·Òªk½ü¥\¡C¦b©Ò¦³¦®¦b¼W¶i°·±dªº¤£¦P¤èªk¤¤¡Aªk½ü¥\¦b¤¤°ê¤H¤¤´¶¤Î³Ì§Ö¡A¼vÅT¤O³Ì¤j¡C1998¦~¡A¦b¥_¨Ê¡BªZº~¡B¤j³s¦a°Ï©M¼sªF¬Ù¡A¥Ñ·í¦aªºÂåÀø¾÷ºc¶i¦æ¤F¤­¶µ¿W¥ßªº°·±d½Õ¬d¡C±Ä¼Ë¤H¸s¶W¹L35¡A 000¤H¡A¬O¨´¤µ¹ïªk½ü¥\­×·ÒªÌ³Ì¨t²Î©M¥þ­±ªº°·±d½Õ¬d(http://www.pureinsight.org/sci/sci/ eng/newscontent.asp?ID=14248)¡C¬°¤F±´´M­×·Ò¤H°·±d¨ü¯qªº¤À¤l¾÷²z¡A§Ú­Ì¦b°ò¦]¤ô¥­¤W¬ã¨s¤Fªk½ü¥\­×·ÒªÌ¶Ý¤¤©Ê¥Õ¦å²yªº°ò¦]ªí¹F¡A¥D­nªºµo²{Á`µ²¦p¤U¡C

³±¶§¥­¿Å°ò¦¤Wªº§K¬Ì½Õ±±

¦³ÃÒ¾Úªí©ú¤ßÆF­×·Ò©M¨­¤ßÁë·Ò¤èªk¯à¼W¶i§K¬Ì¨t²Îªº®Ä¤O¶i¦Ó¦bÁ{§ÉªvÀø¦UºØ¯e¯f¤¤«Ü¦³®Ä [45-47]¡Cºò±i©M¤£¨}±¡ºü·|³y¦¨§K¬Ì¯¿¶Ã¡A±q¦Ó¾É­P·P¬Vªº¥[¼@[2]¡C¦]¦¹³Ì¦nªº¨¾¤î¶Ç¬V¯f¬y¦æªº¤èªk´N¬O¼W¥[¤H¸s¤¤¨ã¦³¤ÑµM©è§Ü¤O±q¦Ó¨ã¦³§¹¥þ§K¬Ì¤Oªº¤H¼Æ¡C°·±d¤H¨ã³Æ¤ÑµM§K¬Ì¤O¤£¶È¯à¨Ï¨ä¨ã¦³§¹¥þ§K¬Ì¤O¡A¦Ó¥B¯à´î¤Ö¤H¸s¤¤¶Ç¬V¯fªº¬y¦æ¡C

³Ìªñ¡A§Ú­Ì¥Î¢Ò¢Ü¢Ï·L±Æ¦C§Þ³N¤ñ¸û¤F­×·Ò¤H(n=4) ©M«D­×·Ò (n=4) ªº°·±d¤H¶Ý¤¤©Ê¥Õ²Ó­Mªº°ò¦]ªí¹Fª¬ªp¡A§Ú­Ìµo²{­×·Ò¤Hªº¶Ý¤¤©Ê¥Õ²Ó­Mªº°ò¦]ªí¹Fªº¶W±`ÅܤơA¦¹¥~ÁÙ¦³©úÅ㪺¥\¯à¤WªºÅܤơC§Ú­Ì¨Ï¥ÎAffymnetrix ªº¸ü¦³12,000­Ó±´°wªº°ò¦]ªä¤ùµo²{¤F¦³²³¦hªº°ò¦]¦bªí¹F¤ô¥­¤W¦³¬Û·í¤jªº§ïÅÜ¡C¨ä¤¤¦³¨â­¿¥H¤WÅܤơA¨Ã¦b©Ò¦³­×·Ò¤Hªº¥Õ²Ó­M¤¤³£¦³Åܤƪº°ò¦]¦³ 485­Ó¡C235­Ó°ò¦]ªºÅܤƦb6­Ó­×·Ò¤H§e¤£¤@­PÅܤơ]¦³ªº¤W¤É¦³ªº¤U­°¡A¥i¯à»P­Ó¤H­×·Òª¬ªp¦³Ãö¡^¡C¦³·N«äªº¬O¡A¨ä¥L¢±¢´¢¯­Ó°ò¦]§e¦P¦VÅܤơA¢°¢²¢±­Ó°ò¦]¤W½Õ±±¡A¥t¥~¢°¢°¢·­Ó°ò¦]§e¤U½Õ±±¡C¤W¤Éªº°ò¦]¦h©M§K¬Ì¥\ ¯à¦³Ãö¡]¹Ï1¡^¡A¦p§Ü·L¥Íª«ªº¤p¤À¤lÜg¡Ð¨¾¿m¯À(Defensin-3, L12691)¼W¥[¤F6.7 ­¿ ¡]¹Ï3¡^¡A¤zÂZ¯À¤Î¤zÂZ¯À¬ÛÃöªº¡B©M¨ü¤zÂZ¯À»¤¾Éªº°ò¦]³£©úÅã¼W¥[¡A¦Ó¤zÂZ¯Àªº§í¨î¦]¤l¡ASarcolectin «o©úÅã¤U­°[48]¡]¹Ï2¡^¡C«Ü©úÅã¡A½Õ±±ÁͶլO¤zÂZ¯Àªº¥\¯à¼W±j¡C§Ü·L¥Íª«ªº¤p¤À¤l¦b¥Íª«¨¾¿m¨t²Î¤¤°_µÛ«D±`­«­nªº§@¥Î¡A­÷¨Å°Êª«ªº¨¾¿m¯À¬OÄÝ©óÅ餺ªí¹F¶q³Ì°ªªº¼sÃЧܵ߯À¡A¦b¶Ý¤¤©Ê¥Õ²Ó­M¤¤¤×¨ä°ª[49]¡C¨¾¿m¯À¡Ð¢²(¢Ï«¬¨¾¿m¯À)¬O¤@ºØ±a­t¹q²üªº¤p¤À¤lÜg,¡@°_µÛ¤@ºØ«D®ñ¤Æª«©Ê±þ¶Ë·L¥Íª«ªº§@¥Î¡C¢Ï«¬¨¾¿m¯À³q¹Lµõ¸Ñ²Óµßªº²Ó­M½¤°_¨ì¤@ºØ¥ý¤Ñ§K¬Ìªº§@¥Î[50,51]¡C³Ìªñ¡A¢Ï«¬¨¾¿m¯À³Q»{¬°¬O³Ì­«­nªº§Ü·R´þ¯f¬rªº¤p¤À¤l(¸}ª`)¡C¤zÂZ¯À¡Ðgamma,¤]¬O¤@ºØ«D±`­«­nªº§Ü¯f¬rµ¥·L¥Íª«ªº²Ó­M¦]¤l[52]¡C¤zÂZ¯À¥i³q¹L»¤¾É¨ä¥L¦]¤l¨Ó½Õ±±§K¬Ì¤ÏÀ³[53]¡C¹ïÂà°ò¦]¤p¹«©M°ò¦]¯Ê¥¢¤p¹«ªº¬ã¨s§ó¶i¤@¨BªÖ©w¤F¤zÂZ¯À¡Ðgamma¦b§K¬Ì¤è­±ªº§@¥Î[54,55]¡C³o¨Ç°ò¦]ªº¼W°ª©M¥\¯à¤è­±ªº§ïÅܬO¬Û§k¦Xªº¡A¶Ý¤¤©Ê¥Õ²Ó­M¹ï²Óµßªº§]¾½©M±þ¶Ë¯à¤O©úÅã¼W±j (¹Ï4)¡C¦¹¥~¡AI-309¤]©úÅã ¼W¥[(¹Ï3)¡C I-309 ÄÝ©óÁͤƲӭM¦]¤l¡A¥¦ªº¨üÅé¬O·R´þ¯f¬rªº»²§U¨üÅé[56,57]¡A¦]¦¹¡AI-309 ¥i¯à°_µÛ§Ü·R´þ¯f¬r·P¬Vªº§@¥Î¡CI-309¦b­×·ÒªÌÅ餺´¶¹M¤É°ª¥i¯à¬O­×·ÒªÌ¹ï·R´þ¯f¬r¦³©è§Ü¤Oªº­«­n­ì¦]¤§¤@¡]®Ú¾Ú¤@¶µ¥¼µoªíªº¤å³¹¡^¡C·íµM¡A¨¾¿m¯Àªº¼W¥[¥i¯à¬O§Ü·R´þ¯f¬r·P¬Vªº¥t¥~¤@­Ó¦]¯À(¸}ª`)¡C


¹Ï 1. ªk½ü¥\­×·ÒªÌ©M¥¿±`¹ï·Ó²Õ¶Ý¤¤©Ê¥Õ²Ó­M°ò¦]ªí¹FÅܤÆÁ`µ²¡C±q¨È¸Çªk½ü¥\­×·ÒªÌ(¤H¼Æ=¢µ¡A¥­§¡¦~ÄÖ45.9·³¡A¼Ð·Ç®t14.3·³¡^©M¨È¸Ç¥¿±`°·±d¹ï·Ó(¤H¼Æ=¢µ¡A¥­§¡¦~ÄÖ40.3·³¡A¼Ð·Ç®t10.3·³¡^©â¨ú30²@¤É¦å¡A¨x¯À§Ü¾®¡A¾Þ§@¤è®×¥Ñ¨©°ÇÂå¾Ç°|¼f¬d©e­û·|³q¹L¡C©â¨úÀR¯ß¦å¨ì¨x¯À¤Æªºª`®g¾¹¡A¥ß¨è¤ÀÂ÷²Ó­M¡C¥ÎFicoll-Hypaque±K«×±è«×Â÷¤ß¥[¥k±Û¿}¨I­°ªk¤ÀÂ÷¥X¦h§Î®Ö¥Õ²Ó­M©M³æ®Ö²Ó­M¡C¬°¤FÁקK¶i¤@¨B·l¶Ë¡A¨S¦³°£¥h¬õ²Ó­M¡C±N·sÂA¤ÀÂ÷ªº¶Ý¤¤©Ê¥Õ²Ó­MÄa¯B¦bÁC»Ä½w½Ä²G¤¤¡A¥ÎCoulter²Ó­M­p¼Æ»ö­p¼Æ¡CÅã·LÃèÀË´úÃҹ꦳96%¨ì98%ªº²Ó­M¬O¶Ý¤¤©Ê¥Õ²Ó­M¡A¨ä¤¤95%ªº²Ó­M¥i³Q­a¬ßÂűư£ªk¬V¦â½T»{¡C¥ÎQiagen¸Õ¾¯²°´£¨ú©M¯Â¤ÆÁ`®Ö¿}®Ö»Ä¡C5·L§JÁ`®Ö¿}®Ö»Ä¡A T7-d(T)24¤Þª«(GGCCAGTGAATTGTAATACGACTCACTATA GGGAGGCGG-(dT)24)©MSuperscript II (GIBCO-BRL, Rockvill, MD) ¥Î©ó¦X¦¨²Ä¤@±øcDNAÃì¡C²Ä¤G±øcDNAÃ쪺¦X¦¨¤ÏÀ³¦b16¢J¶i¦æ¡C¤ÏÀ³Åé¨t¤¤¥[¤J¤j¸z±ìµßDNA³s±µ×Q¡A¤j¸z±ìµßDNA¦h»E×QI¡A®Ö¿}®Ö»Ä×QH¡AµM«á¥[¤JT4 DNA¦h»E×Q¥H¸É»ô·s¦X¦¨ªºcDNAÃ쪺¥½ºÝ¡CcDNA¦A¸gPLG½¦-×ô/´â¥é©â´£¯Â¤Æ¡A¤A¾J¨I¾ý¡C±N¯Â¤Æ¤FªºcDNA¦b37¢JÂ÷ÅéÂà¿ý¤ÏÀ³¤¤°ö¾i6¤p®É¥H²£¥Í¥Íª«¯À¼Ð°OªºcRNA¡C±N20·L§JcRNA©ñ¦b½w½Ä²G¡]§t200²@¼¯º¸Tris-Acetate, pH 8.1; 500²@¼¯º¸¾L»Ä¹[¡A150²@¼¯º¸¾L»ÄÁâ¡^¤¤¡A95C°ö¾i35¤ÀÄÁ¨Ï¤§¦¨¬°¤ù¬q¡CcRNA¤ù¬q©M¸g¹L¹w¥­¿ÅªºAffymetrix¥Íª«´¹¤ù¦b45¢JÂø¥æ 14¦Ü16¤p®É¡CÂø¥æ«á²¾¥h¤ÏÀ³²G¡A¥Î§C±j«×½w½Ä²G¡]6X¼Ð·ÇÁC»ÄÆQ·»²G¥[EDTA¡A0.01% Tween 20, 0.005%§Üªwªj¾¯¡^¬~10¦¸¡AµM«á¥Î°ª±j«×½w½Ä²G¡]100 ²@¼¯º¸ MES¡A 0.1 ¼¯º¸´â¤Æ¶u¡A0.01% Tween 20¡^¬~4¦¸¡A¥ÎSAPE¬V¦â¡C¥Î¥Íª«¯À¼Ð°Oªº¤p¹«§ÜAvidin§ÜÅé¹å¨|«á¡A¦A¥ÎSAPE¬V¦â¡C¥Íª«´¹¤ù¥Î´f´¶´¹¤ù±½´y»ö±´´úÂø¥æ«H¸¹¡CÂø¥æ«H¸¹¥Í¦¨ªº¤å¥»¤å¥ó¿é¤J¨ì·L³nExcel¶i¦æ¸ê®Æ¤ÀªR¥H§ä¥Xªk½ü¥\­×·ÒªÌ©M¥¿±`¹ï·Ó²Õ¤§¶¡ÅܤƹF¨â­¿¥H¤Wªº«H¸¹¡CÀË´ú¤F¥|­Óªk½ü¥\­×·ÒªÌªº12,000­Ó°ò¦]¡C¦³ 485­Ó°ò¦]µo¥Í¤FÅܤơA¨ä¤¤132­Ó°ò¦]¡]¦ûÅܤƼƪº27%¡^«ùÄò¤U½Õ¡A118­Ó°ò¦]¡]¦û24%¡^«ùÄò¤W½Õ¡C



¹Ï2. ¤zÂZ¯À¬ÛÃö°ò¦]ªºÅܤơC¥|­Óªk½ü¥\­×·ÒªÌ©M¥|­Ó¥¿±`¤H¤zÂZ¯À¬ÛÃö°ò¦]Åܤƪº¤ñ¸û¡C¼Æ¾Ú¬O¥Hmean + SD ªí¥Ü¡C¥¿¼Æªí¥Ü¼W¥[ªº­¿¼Æ¡A­t¼Æªí¥Ü´î¤Öªº­¿¼Æ¡C


¹Ï3. §Ü·L¥Íª«Üg°ò¦]ªº¤W½Õ¸`¡Cªk½ü¥\­×·ÒªÌI-309©M¨¾¿m¯ÀªºÅܤơC§÷®Æ©M¤èªk¨£¹Ï1»¡©ú¡C


¹Ï 4. ªk½ü¥\­×·ÒªÌ¶Ý¤¤©Ê¥Õ²Ó­Mªº§Üµß¬¡©Ê¼W¥[¡C¸²µå²yµß¡]SA¡^¥Î§@±þµß¬¡©ÊÀË´úªº©³ª«¹v²Ó­M¡C¿ï¥Î¹ï¼Æ¥Íªø¤¤´Áªº¸²µå²yµß¡C±N¹v²Ó­M¸²µå²yµß©M¶Ý¤¤©Ê¥Õ²Ó­M¥H¤£¦Pªº§@¥Îª«/©³ª«¤ñ²V¦X¡A¦b37¢J°ö¾i2­Ó¤p®É¡C2¤p®É«á§@¨t¦Cµ}ÄÀ¶îã¯×½L¡A¼Æµß¸¨¼Æ¥H©w¶q±þµß¬¡©Ê¡C¥Î²Óµß©M¶Ý¤¤©Ê¥Õ²Ó­M²V¦X°ö¾i«áªº¬¡µß´î¤Ö¼Æ¨Ó©w¶q¶Ý¤¤©Ê¥Õ²Ó­Mªº³Ì¤j±þµß¬¡©Ê¡C²Óµßªº³Ì²×¿@«×¥Hã¯×½L¤Wªºµß¸¨¼Æ­pºâ¡C±þµß¬¡©Ê¥H±þ¦º²Óµßªº¦Ê¤À¤ñ­p¡C¦p¹Ï©Ò¥Ü¡A»P¥¿±`¹ï·Ó²Õ¬Û¤ñ¡Aªk½ü¥\²Õªº¶Ý¤¤©Ê¥Õ²Ó­M±þµß¬¡©Ê¦³ÅãµÛ¼W¥[¡A±þ¶Ë¤Oªº¼W¥[¦b¥Õ²Ó­M¡G²Óµß¥ô¦ó¤ñ¨Ò¤U³£¦³ÅãµÛªº²Î­p¾Ç®t²§¡]P<0.0001¡^¡C

µM¦Ó¡A§K¬Ì¤ÏÀ³´N¹³¤@¬`Âù¤b¼C¡C·í¥¦«ùÄò¤ÏÀ³®É¡A¹L«×ªº§K¬Ì¨t²Îªº¿E¬¡´N¥i¯à¹ï¥DÅ馳®`[58]¡C¨º»ò­×·Ò¤Hªº§K¬Ì¨t²Î¬O¦p¦ó¸Ñ¨M³o¤@ÃøÃDªº©O¡H§Ú­Ìµo²{¤F¥t¤@ºØ¶W±`ªº½Õ±±¡ABCl-2©MBCl-XL¡A³o¨Ç½Õ±±²Ó­M¦º¤`ªº°ò¦]ªí²{¬°ÅãµÛ¦a¤U½Õ±±(¹Ï5)¡C BCl-2©MBCl-XLÄÝ©óBCl-2®a±Úªº§Ü²Ó­M¦º¤`¦¨­û[59,60]¡C³o¨Ç§Ü²Ó­M¦º¤`°ò¦]ªº´î¤Ö¥i¯à¨Ï­×·Ò¤Hªº¶Ý¤¤©Ê¥Õ¦å²y¦b¨ü»Eà­¿}(lipopolysaccharide, LPS) ®É¥[³t¦º¤`(¹Ï6a©M¹Ï7)¡CLPS¬O¤@ºØª¢¯g«P¶i¾¯¡A¯à°÷¨ë¿E²Ó­M¨Óªí¹F²Ó­M¦UºØ¦U¼Ëªºª¢¯g¦]¤l[60]¡C«Ü¦hºC©Êª¢¯g·l¶Ë»P¨ü¨ë¿Eªº¶Ý¤¤©Ê¥Õ¦å²yªº¦º¤`©µ¿ð¦³Ãö[61]¡C¦Ó»¤¾É²Ó­M¦º¤`«o¦³§Q©ó±±¨îª¢¯g [62]¡C ¥t¥~¡A²Ó­M¦º¤`»¤µoªº°ò¦]ÅãµÛ¦a«o¤Ï¦V¤W½Õ±±¡A¨ä¤¤¥]¬A¸~½FÃa¦º¦]¤l¨üÅé-1 ¬ÛÃö³J¥Õ¡]TNF-receptor-1 associatedprotein), BH3 ¬Û¤¬§@¥Î°ò¹Î¦º¤`«P¶i¦]¤l¡]BH3 interacting domain death agonist), ¥Õ²Ó­M¤¶¯À-1 Âà´«×Q(Interleukin-1 convertase), ©M¥Õ²Ó­M¤¶¯À-1Âà´«×Q2 ( Interleukine-1-converting enzyme2)¡C³o¨Ç«P¶i²Ó­M¦º¤`ªº¦]¤lªº¼W¥[¥i¯à¬O­×·Ò¤H¨ü¨ë¿Eªº²Ó­M¥[³t¦º¤`ªº¥t¤@­Ó¦]¯À(¹Ï5)¡C¡@


¹Ï5. ²Ó­M­ä¹s¦º¤`¬ÛÃö°ò¦]ªºÅܤơC§÷®Æ©M¤èªk¨£¹Ï1»¡©ú¡C


¹Ï 6. ªk½ü¥\­×·ÒªÌ¶Ý¤¤©Ê¥Õ²Ó­M­ä¹s¦º¤`ªºÅܤơC¶Ý¤¤©Ê¥Õ²Ó­M¥H¾A·í¿@«×­«·s²V¤Ã¦b§t10%¤p¤û¦å²MªºRPMI1640°ö¾i²G¤¤¡C¦N©iÂĬV¦âÃÒ¹ê¤ÀÂ÷¥Xªº¦h§Î®Ö¥Õ²Ó­M¯Â«×°ª©ó80%¡A¨ä¤¤ªº³æ®Ö²Ó­M¤Ö©ó1%¡C¥x¬ßÂűư£ªkÃҹꬡ²Ó­M°ª©ó98%¡C¨ë¿E²Ó­M¥Î¤º¬r¯À¡]25·L§J/²@¤É¡^¡C¶Ý¤¤©Ê¥Õ²Ó­M¦b¦³©Î¨S¦³¤º¬r¯À¨ë¿Eªº±ø¥ó¤U°ö¾i¤£¦P®É¶¡¡C²Ó­M¦º¤`¥ÎRoche¤½¥qªºÀË´ú²°´ú©w¡C¨ãÅé°µªk¬O¡A1x10^4 ¶Ý¤¤©Ê¥Õ²Ó­M°ö¾i¦b200·L¤É§t3%¤p¤û¦å²MªºRPMI 1640°ö¾i²G¤¤¡A¸m©ó96¤Õ°ö¾iªO¤¤37¢J°ö¾i¡A¦b¤£¦Pªº®É¶¡ÂI¦¬¼Ë¡CÂ÷¤ß¦¬¶°²Ó­M¡A±N²Ó­M­«·sÄa¸m¦b·»²Ó­M²G¤¤¡AµM«áÂ÷¤ß¦¬¶°§¹¾ãªº²Ó­M®Ö¨I¾ý¡C±N§t®Ö¤pÅ骺¤W²M²G²¾¨ìStreptavidin¥]³Qªº96¤Õ×QÁpªO¡A»P¥Íª«¯À¼Ð°Oªº§Ü²Õ³J¥Õ§ÜÅé¡A¶W®ñª[¤Æ×Q¼Ð°Oªº§Ü-DNA§ÜÅé¦@¦P¹å¨|¥H§Î¦¨§ÜÅé-®Ö¤pÅé½Æ¦Xª«¡C¬~«á¡A¥[¤J¶W®ñª[¤Æ×Q©³ª«ABST¹å¨|¡C¦b405¯Ç¦Ì¥ú¤U´ú©w§l¦¬¡C³o­Ó×QÃì¤ÏÀ³ªºµ²ªGÅã¥Üªk½ü¥\­×·ÒªÌªº²Ó­M­ä¹s¦º¤`¦b¤º¬r¯À¨ë¿E¤U¦³ÅãµÛ¼W¥[¦Ó¦b¨S¦³¤º¬r¯À®ÉÅãµÛ´î¤Ö¡C* ªí¥Ü§¡­È¦³ÅãµÛ©Ê®t²§¡AP­È¤p©ó0.01¡CtÀËÅç¡C¸ê®Æ¨Ó¦Û7¦Wªk½ü¥\­×·ÒªÌ©M7¦W¥¿±`¹ï·Ó¡A±Ä¼Ë®É¶¡ÂI¬O0¡A2¡A4¡A8©M16¤p®É¡C

²Ó­M¦º¤`¦³Ãö°ò¦]ªº§ïÅÜ¥i¯à¾É­P¤F·Ò¥\¤H¶Ý¤¤©Ê¥Õ²Ó­M¤¤ªí²{ªºLPS¨ë¿E¦º¤`ªº¥[³t(¹Ï7)¡C¶Ý¤¤©Ê¥Õ²Ó­Mªº¥[³t¦º¤`¯à¤Þ°_ª¢¯gªº¨³³t®ø¥¢¡A±q¦Ó­­¨î¤F¥Ñ©ó§K¬Ì¨t²Îªº¼W±j¦Ó¤Þ°_ªº¦Û§Ú·l¶Ë[63-65]¡C¦p¹Ï6©M¹Ï7©Ò¥Ü¡A¦b¨S¦³LPS¨ë¿Eªº±¡ªp¤U¡A·Ò¥\¤H¶Ý¤¤©Ê¥Õ²Ó­Mªº¦s¬¡¦³ÅãµÛªº©µªø¡A¦Ó³oºØ²Ó­M¹Ø©Rªº©µªø¤]¥i¯à»P·Ò¥\©Ò¾É­Pªº·s³¯¥NÁ¤ô¥­¤U­°¦³Ãö¡C¦b«Dª¢¯gªºª¬ªp¤U¡A¨M©w¶Ý¤¤©Ê¥Õ²Ó­M¦b«Dª¢¯g±¡ªp¤U¦Ûµo©Ê¦º¤`ªº¦]¯À¬O®ñ¤Æ¦Û¥Ñ°ò¡A¦Ó¤£¬O­P¦º°ò¦] [66,67]¡C§Ú­Ìªº¼Æ¾ÚÅã¥Üªk½ü¥\¤Î¨ä¥¦¥´§¤­×·ÒªÌªº¶Ý¤¤©Ê¥Õ²Ó­M¨ü¬¡©Ê®ñ¤Æ¾¯ªº¤z¹w¤U­°¡C¦³¨ä¥L¬ã¨s¤]»¡©ú¦å¯×¹L®ñ¤Æµ{«×ªº¤U­°¥i¯à¸ò¥´§¤¤J©w¤Þ°_ªººò±iª¬ºA­°§C±K¤Á¬ÛÃö[68]¡C


¹Ï 7. ­Pª¢¦]¤l¤º¬r¯À¹ï¶Ý¤¤©Ê¥Õ²Ó­M­ä¹s¦º¤`ªº¼vÅT¡C¤ÀÂ÷©M³B²z¶Ý¤¤©Ê¥Õ²Ó­Mªº¤èªk¦p¹Ï6»¡©ú¡C¤£¦P®É¶¡ÂI¨ú¼Ëªº²Ó­M¸gWeightªk¬V¦â¦b¥úÃè¤UÀˬd¡A­ä¹s¦º¤`ªº²Ó­M¥Ñ¬õ°é°é¥X¡C½bÀY©Ò«üªº¶Ý¤¤©Ê¥Õ²Ó­Mªí²{¥X¬V¦â½è¿@ÁY¡A®ÖÅܶé¡A­M¼ßªÅªw§Î¦¨©M²Ó­MÁY¤p¡C¶Ý¤¤©Ê¥Õ²Ó­M¦b¦³©Î¨S¦³¤º¬r¯À¨ë¿Eªº±ø¥ó¤U°ö¾i16¤p®É¡C¦p¹Ï©Ò¥Ü¡Aªk½ü¥\­×·ÒªÌªº¶Ý¤¤©Ê¥Õ²Ó­M¦b¨S¦³¤º¬r¯À¨ë¿E®É¤j¦h¼Æ¤´¦s¬¡¡A¨ü¨ë¿E®É«o¤j³¡¥÷¥X²{¤F­ä¹s¦º¤`¡C»P¦¹¬Û¤Ï¡A¥¿±`¹ï·Ó²Õªº¶Ý¤¤©Ê¥Õ²Ó­M¦b¨S¦³¤º¬r¯À¨ë¿E®É¬O­ä¹s¦º¤`¡A¨ü¨ë¿E®É«h¦s¬¡¡C


¹Ï 8. §K¬Ì¨t²Î³±¶§¥­¿Å¥Ü·N¹Ï¡C§K¬Ì­@¨ü©M§K¬Ì¿E¬¡¬O¹ï¥ß¦Ó¤S¬Û¤¬¨Ì¿àªº¡]a¡^¡C§K¬Ì­@¨ü¥i¥H«OÅ@±J¥D¤£³Q¦Û§Ú·l¶Ë¡A¦Ó§K¬ÌºÊµø/¿E¬¡«h¬O®ø·À¨ü·l©MÅܲ§ªº²Ó­M¨Ã«OÅ@¾÷Å餣³QÅܲ§ªº²Ó­M¼vÅT©M¯f­ìÅé«I¤J¡C¤£¹L¡A³±¤¤ÁÙ¥²¶·¦³¶§¡A¦]¬°¥u¦³§K¬Ì­@¨ü¦Ó¨S¦³§K¬Ì¿E¬¡¯à¾É­P¾÷Åé©ö±wÀù¯g©M·P¬V©Ê¯e¯f¡F¤Ï¤§¡A¶§¤¤¤]¥²¶·¦³³±¡A¦]¬°¨S¦³¦Û§Ú­­¨îªº§K¬Ì¿E¬¡·|¾É­PÄY­«ªº¦Û§Ú·l¶Ë¡C¹Ï8Åã¥Ü¤Fªk½ü¥\­×·ÒªÌ¥H³±¶§¥­¿Å¬°°ò¦ªº½Õ¸`¡Cªk½ü¥\­×·ÒªÌªº¶Ý¤¤©Ê¥Õ²Ó­Mªí²{¥X­Pª¢°ò¦]¡]§Ü­ä¹s¦º¤`°ò¦]¡^ªº´î¤Ö©Mª¢¯g¶É¦V±o¥H­­¨î¡]³±¡^¡A¦P®É§K¬Ì²Ó­Mªº§K¬Ì¤O¼W±j¡]¶§¡^¬O¬°¶§¤¤¦³³±¡C»P§K¬Ì¤O¼W±j¦³Ãöªº§ïÅÜ¥Nªí¤F³±¤¤¶§ªº³¡¥÷¦b²Ó­M³B©ó§C¬¡©Ê®É¡]§C¥NÁ¡^«OÅ@¾÷Åé§K©ó·L¥Íª««I¥Ç¡C­×·ÒªÌªº¶Ý¤¤©Ê¥Õ²Ó­M¬O§C¥NÁ§C­Pª¢ªº¡A«o¨ã¦³§K¬Ì¤O¼W±jªº¤À¤l¡A¬O¬°³±¤¤¦³¶§¡C¥Ñ©ó¯Ê¥F§Ü­ä¹s¦º¤`°ò¦]¡A¿E¬¡ªºª¢¯g²Ó­M·|³Q§Ö³t±Æ°£¡A¥Ñ§K¬Ì¤O¤W½Õ¸`¾É­Pªº¤£§Q¦]¯À¦]¦Ó³Q©è®ø¡C

¤¤Âå»{¬°¡A³±¶§½Õ©M¬°°·±d¤§¥»¡C³±¶§½Õ©M³o¤@²³æ«o·¥¬°­«­nªºªk«h¦b°·±d¡BÂå¾Ç©M¤j¦ÛµM¤¤¨ì³B³£¯àÅé²{¥X¨Ó¡C³±¶§²z½×¤]¥i¥Î¨Ó¸ÑÄÀ²{¥N§K¬Ì¾Çªº·§©À¡A¦p§K¬Ì­@¨ü©Ê©M§K¬Ì¬¡©Ê¡C§K¬Ì­@¨ü(³±)©M¿E¬¡(¶§)ªº¥­¿Å¬O¤@­Ó¥Í¦º§ñÃöªº°ÝÃD(¹Ï8a)¡C§K¬Ì­@¨ü©M¿E¬¡¬O¹ï¥ß¦Ó¤S¬Û¤¬¨Ì¿à(¬Û¥Í¬Û«g)¡C§K¬Ì¨t²Î¬¡©Ê¹L§Cªº¸Ü¡A·|¨Ï§K¬ÌºÊ·þ¤£¯à¥¿±`¶i¦æ¡A±q¦Ó³y¦¨¬ðÅÜ©Mª¢¯g²Ó­M¤£¯à¤Î®É±Æ°£¡A³o±N¾É­PÀù¯g©MºC©Êª¢¯gµ¥¡C¦ý§K¬ÌºÊ·þ¡þ¿E¬¡(¶§)¤S¤£¯à¹L±j¡A¦]¬°¨º·|³y¦¨¹ï¦Û¨­ªº¶Ë®`¡A©Ò¥H´N»Ý­n¦Û§Ú­­¨î¹ï¨äªº¨î¬ù¡C¤ñ¦p¡Aª¢¯g²Ó­M¥²¶·¥Î²Ó­M¦º¤`ªº½Õ±±¨Ó²M°£¡A±q¦Ó®ø°£©M°±¤îª¢¯g¤ÏÀ³(¶§¤¤¦³³±)¡C§K¬Ì­@¨ü¦b¨Ï¥Í©R«O«ù©M¿Ó©Ê¤è­±«D±`­«­n¡A¦ý¶È¶È­@¨ü¦Ó¨S¦³§K¬ÌºÊ·þ¡þ¿E¬¡¤Æ·|¾É­P·P¬V¡AÀù¯g¡A©Î¦Û¨­§K¬Ì¯e¯f¡A³o¬O³±¶§¬Û¤¬§@¥Îªº¨å«¬ªí²{¡C¦]¦¹¡A¶§¤¤¥²¶·¦³³±¡C¥Ñ¨­¤ß¬Û¤¬§@¥Î¤Þ°_ªº½Õ±±¬O¤@ºØ³±¶§½Õ©Mªº¥­¿Å¡A±q¦Ó¨Ï±o§K¬Ì¨t²Îªº¡§Âù¤b¼C¡¨ªº¯S©Ê±o¨ìªÈ¥¿¡A¤]´N¬O»¡§K¬Ì¤O¥i¥H¤W¤É¦Ó¤£·|¦³¤Ï§@¥Î¡C¦bºë¯«¼h­±¤W­×·Òªº¤H¡A¥L­Ì¶Ý¤¤©Ê¥Õ²Ó­M¤¤­P¦º°ò¦]ªº§ïÅܤä«ù¤F³oºØ°²»¡(¹Ï8b)¡C®ð¥\½m²ßªÌ¶Ý¤¤©Ê¥Õ²Ó­M¤¤§Ü²Ó­M¦º¤`°ò¦]ªº¤U½Õ±±«P¦¨¤Fª¢¯g²Ó­Mªº¨³³t²M°£¡A¦Ó°·±d¶Ý¤¤©Ê¥Õ²Ó­Mªº¦s¬¡´Áªº©µªø¡A«h¥i¯à¬O¥Ñ©ó¥´§¤¤J©w¤Þ°_ªº²Ó­M¥NÁ¤ô¥­¤U­°±q¦Ó¨Ï®ñ¤Æ¦Û¥Ñ°òªº´î¤Ö©Ò­P¡A³oºØÂù¦V½Õ±±¦³®Ä¦a«O«ù¤F§K¬Ìªº³±¶§¥­¿Å¡C¥´§¤¤J©w©Ò³y¦¨ªº¥NÁ¤ô¥­¤U­°¡]¨£¤U¤å¡^¦Ó¨Ï¾÷Åé³B©ó¤@ºØ§C¤ÏÀ³ª¬ºA(³±)¡A§K¬Ì¬¡©Ê´N·|¼W±j(¶§)¡A¤zÂZ¯À©M¨¾¿m¯À¼W¥[¤Î§]¾½¥\¯à¼W±j)±q¦Ó¨Ó¥­¿Å«OÅ@³oºØ§C¤ÏÀ³ª¬ºA¡C³oºØÂù¦V½Õ±±ªº²{¶H±N·|¬°§Ú­ÌªvÀø¤è°w¥tÅPÁÑ®|¡A¦pªG§K¬Ì¤ÏÀ³¯à°÷¤U½Õ¦Ó¤S¤£¼vÅT¾ãÅé§K¬Ì¤O¡A´N¯à¹ï²¾´Ó±Æ¥¸¡A¦Û¨­§K¬Ì¯e¯f©M¹L±Óµ¥ªºªvÀø¦³·¥¤jªºÀ°§U[69]¡C¤Ï¤§¡A¦pªG°ò©ó³±¶§½Õ©M°ò¦¤Wªº§K¬Ì½Õ±±¥i¯à·|¬OªvÀø¦hºØ§K¬Ì¯e¯fªº¤S¤@ºØ¿ï¾Ü¡C

·s³¯¥NÁ²vªº­°§C©M²Ó­M¡§©U§£½c¡¨ªº´î¤Ö

²Ó­Mªº·s³¯¥NÁ°ª§C¨M©w¤F³J¥Õ½è¦X¦¨©M­°¸Ñªº³t²v¡CµM¦Ó¡A³J¥Õ½è¦X¦¨©M­°¸Ñªº¸gÀ٩ʪø´Á¥H¨Ó¤@ª½³Q¤H©¿µø¡Aª½¨ì­«·s²z¸Ñªx¯À¨Ì¿à©Êªº³J¥Õ½è­°¸Ñ¨t²Î (Ubiquitin-dependent protein degradation pathway, UPP)[70]¡C¦b¯u®Ö²Ó­M¤¤·lÃaªº¡A²§¤Æªº¡A©M¦Ñ¤Æªº³J¥Õ½èªº¥D­n³B²z¨t²Î¬OUPP[71]¡C¦b¥¿±`¤Hªº²Ó­M¤¤¡A¤j¶q·s¦X¦¨ªº¤£¥¿±`ªº³J¥Õ½è³£·|³q¹L UPP¨Ó­°¸Ñ¡A³o¥i¯à¬O¦]¬°¥¿±`¤H²Ó­Mªº·s³¯¥NÁ²v¤]¼W°ª©Ò­P¡C¨Ò¦p¡A¤@­Ó²Ó­M¨C¤ÀÄÁ¯à¦X¦¨2E6­Ó®Ö¿}Åé³J¥Õ½èªº«þ¨©¡A¨ä¤¤¬ù¦³¶W¹L30%·s¦X¦¨ªº³J¥Õ½è¥ß§Y´N³QUPP¾P·´¤F¡C¦b¯f²z±ø¥ó¤U¡A³Q°e¤JUPP­°¸Ñªº³J¥Õ½è·|ÅãµÛ¼W¥[¡A¤j¶qªº¤HÃþ¯e¯f¥i¯à©MUPP³£¦³Ãö«Y[71-74]¡C

UPP ¥i¥H³q¹L­×¹¢²Ó­M¤º¦UºØ¦U¼Ëªº³J¥Õ½è¡A°Ñ»P«Ü¦h­«­nªº¡A°ò¥»ªº²Ó­M¬¡°Ê¡C³o¨ä¤¤¥]¬A²Ó­M©P´Á¡A¤Àµõ¡A¤À¤Æ¡A©Mµo¥Íµo¨|ªº½Õ±±¡A²Ó­M¹ï¨ë¿E©M¥~¬É¦]¤lªº¤ÏÀ³ªº½Õ±±¡A¯«¸g¨t²Îªº§ÎºAµo¥Í¡A²Ó­Mªí­±ªº¨üÅé©MÂ÷¤l³q¹Dªº¤U½Õ±±¡A³J¥Õ½è¤Àªcªº©w¶q½Õ±±¡ADNA­×´_¡A§K¬Ì©Mª¢¯g¤ÏÀ³ªº½Õ±±¡A¥H¤Î²Ó­M¾¹ªº¥Í¦¨µ¥µ¥¡C¤w½T©wªº­n³q¹LUPPªº²Ó­M³J¥Õ½è¦³´X¦Ê¤§¦h¡A¦Ó¥B³o­Ó¦W³æÁÙ¦bí¨B¼Wªø¡C³J¥Õ½è°ò½èªº¦h¼Ë©Ê©Mµ²ºcªº½ÆÂø©Ê¡A¨Ï±o³o¤@¨t²Î©M³\¦h­«­n¯e¯fªºµo¯f¾÷²zÁpô°_¨Ó¡A¥]¬A°ò¦]¯e¯f¡B¯«¸g²Ó­M°h¦æ©Ê¯e¯f¡BÀù¯g¡B¦ÙµäÁY¡B°ª¦åÀ£¡B¥Õ¦å¯f¡B¦Û¨­§K¬Ì¯e¯f¡Bª¢¯g¡B¦Ñ¦~©Ê¥¢½Õ¡C³Ìªñ¡A¦³ªì¨B¸ÕÅçµ²ªGªí©ú¡A UPPªº³J¥Õ×Qªº§í¨î¾¯¥i¯à¹ïÀù¯g¦³ªvÀø§@¥Î[75,76]¡C«Ü¦h±¡ªp¤U¡A»PUPP¦³Ãöªº¯e¯f³£¬O¦]¬°¹L°ªªº·s³¯¥NÁ²v¡C¥¦´N¹³¤@­Ó¤À¤l¶Ç·P¾¹¡A¨ä¬¡©Ê·|ÀHµÛ¥~¬É©M¤º¦bªºÀ³¤O¼W¥[¦ÓÅܤơC¦]¬°³o­ÓÅé¨t´N¹³©U§£³B²z¯¸¡AÁ`¬O§â¤Ï±`ªº©M¯}·lªº²Ó­M©ì¶i¨Ó¤À¸Ñ±¼¡A§Ú­Ì§â¥¦¤ñ³ë¦¨¤@­Ó²Ó­M¤¤ªº¶Â¬}¡C


¹Ï9. UPP½Õ¸`°ò¦]ªº¤U½Õ¸`¡C§÷®Æ©M¤èªk¨£¹Ï1»¡©ú¡C


¹Ï10. ºò±i¬ÛÃö°ò¦]ªº§ïÅÜ¡C§÷®Æ©M¤èªk¨£¹Ï1»¡©ú¡C


¹Ï11. ®Ö¤pÅé³J¥Õ¬ÛÃö°ò¦]ªº¤U½Õ¸`¡C§÷®Æ©M¤èªk¨£¹Ï1»¡©ú¡C

UPP ªº¥D­n¦¨¥÷¬Oªx¯À¡AUPP¨t²Î¦³¤TÃþ¥D­nªº×Q¡GE1(ubiquitin activating enzyme, ªx¯À¿E¬¡×Q)¡AE2(ubiquitin conjugating enzyme, ªx¯À¥æÁp×Q)©ME3(ubiquitin ligase, ªx¯À³s±µ×Q)70¡CRING(Really Interesting New Gene, »¤¤Hªº·s°ò¦])RING-finger³J¥Õ½è¬O¤@²Õªñ¨Ó¤~©ú½T¨ä¯S®í¥\¯àªº³J¥Õ½è[77]¡C¶V¨Ó¶V¦hªº¬ã¨sªí©ú¦b¯S©wªºªx¯À¤ÏÀ³¤¤RING-finger ³J¥Õ½è°_µÛ¥D¾É§@¥Î¡A¦Ó¥B¥i¯à©Ò¦³ªºRING-finger³J¥Õ½è³£¬OE3«¬ªx¯À-³J¥ÕÁpµ²×Q[78,79]¡C§Ú­Ìµo²{¤jªk­×·ÒªÌ¨­¤W¤ÀÂ÷¥Xªº¶Ý¤¤©Ê¥Õ²Ó­M¡A¨äªx¯À¡BE2©ME3ªº°ò¦]ªí¹F¶q¦³©úÅ㪺¤U½Õ±±ÁͶÕ(¹Ï9)¡C¦b©Ò¦³§Ú­Ì½T»{ªºRING-finger³J¥Õ½è¤¤¡A¥u¦³ÄÝ©óRBCC®a±Úªº§tTRIM ªºRING ³J¥Õ½è¬O¤W½Õ±±ªº[80]¡C¬Û·í¦³·N«äªº¬O¡A¦³7­Óªx¯ÀE3°ò¦]¦P®É¤U½Õ(¹Ï9)¡C¦¹¥~¡A¤@ºØ»PUPPµLÃöªº³J¥Õ½è­°¸Ñ×Q¡Aornithine decarboxylase antizyme [81]¡A¤]¦³ÅãµÛ´î¤Ö(¹Ï10)¡CUPP¨t²Îªº¤U½Õ¥i¯à¬O¦]·s³¯¥NÁ²vªº¤U­°¦Ó«D¥´§¤¤J©wªºª½±µ®ÄÀ³¡C¾Ú³ø¾É¡Aªx¯À¬O¤@­Óºò±i©Î¼ö¥ð§J½Õ±±ªº°ò¦][82,83]¡C¤£¹L¡A¥Ø«e¨S¦³¤åÄm³ø¾ÉUPP¨t²Î¤¤¨ä¥¦ªº¦¨¤À¤]¯àÀHºò±i©Î¼ö¥ð§J½Õ±±¡C¥H¤U´y­zªº¨ä¥¦»Pºò±i¨ë¿E¦³Ãöªº°ò¦]ªºÅܤƤ]»¡©úUPPÅé¨tªº¤U½Õ±±¥i¯à¬O­Ó«Dª½±µ¹Lµ{¡C

¨ä¥¦¤U½Õ±±ªº°ò¦]¥]¬A¡A°Ñ»P³J¥Õ½è¦X¦¨ªº°ò¦]¡ADNA­×¸Éªº§Ü®ñ¤Æ×Q¡C¥D­nªº§Ü®ñ¤Æ×Q¡A¹L®ñ¤Æ²B×Q©M¨¦¯Ö¥ÌÜg¹L®ñ¤Æ²B×Q¡A¤]´î¤Ö¤F(¹Ï10)¡C³o¨Ç»Pºò±i¨ë¿E¬ÛÃöªºÃöÁä×Qªº´î¤Ö¡A¥H¤Î¨ä¥¦¨üºò±i¨ë¿E½Õ±±ªº°ò¦]¤U­°¡A·N¨ýµÛ®ñ¤Æª«ªº¥Í¦¨©M¤j¤À¤lªº¯}Ãa´î¤Ö¡A³o¨Ç°ò¦]¥]¬A»Ã¥À°ò¦]¦b­÷¨Å°Êª«Å餺ªº¦P·½°ò¦]RAD52(§Ü¿ç®g)©MERCCs(¤Á°£­×¸É)¡C®Ö¿}Åé¬O³J¥Õ½è¦X¦¨¤¤­«­nªº¦¨¤À¡A¦Ó11­Ó®Ö¿}Åé°ò¦]¤¤10­Ó¤U­°»¡©ú³J¥Õ½è¦X¦¨¤]¥i¯à¤U­°(¹Ï11)¡C¥O¤H·N·Q¤£¨ìªº¬O¡A¨â­Ó¼ö¥ð§J³J¥Õ½è¡AHSP70©MHSP40-3¡A«oÅãµÛ¤W¤É¡A ³o»P¨ä¥¦¹ïºò±i¨ë¿E¦³Ãöªº°ò¦]ªº¤U­°«ê«ê¬Û¤Ï(¹Ï10)¡C ³o¨Çºò±i¨ë¿E½Õ±±°ò¦]¤Ï¦V½Õ±±ªº¤À¤l¾÷²zÁٻݭn¶i¤@¨B½T©w¡C¦ý¹ï©óÃþ¦ü³o¨Ç¼ö¥ð§J°ò¦]¡A¬ã¨s¬O§_¥i¥H³q¹L¤W½Õ±±¨Ó°_¨ì«OÅ@§@¥Î¬OÀ³¸Ó«Ü¦³·N«äªº¡C¦³ÃÒ¾Úªí©ú³o¨Ç¼ö¥ð§J³J¥Õ¥i¯à¹ï¤ßŦ½T¦³«OÅ@§@¥Î[84]¡C

³o¤@¶µ¥Î¢Ò¢Ü¢Ï·L±Æ¦C§Þ³N¬ã¨s¦b°ò¦]ªº¤ô¥­¤W¬ã¨s°ò¦]ªí¹Fª¬ªp»¡©ú¡A·Ò¥\¤H²Ó­Mªº¥NÁ²v¦³¤U­°ÁͶաCUPP¨t²Îªº¤U½Õ¥i¥H¥Î¨âºØ²z¥Ñ¸ÑÄÀ¡A1)©³ª«¨Ì¿à©Êªº¤U½Õ¡A¦]¬°¥NÁ²vªº¤U­°¤Þ°_¥NÁ²£ª«ªº´î¤Ö¾É­P¤F¼oª«³B²zUPP¹Lµ{ªº¤U½Õ¡A2)¥´§¤¤J©w¤Þµoªº²Ó­M¬¡°Ê¬YºØµ{«×¤Wª½±µ¾É­P¤FUPP°ò¦]ªí¹FªºUPP¨t²Îªº¬Y¨Ç¤À¤lÂà¿ý¤ô¥­¤U­°¡C¹ï©óUPP¨t²Îªº¤U½Õ¥i¯à»P­×·Ò¤Hªº°·±dªí«¬¦³Ãö³o¤@°ÝÃD¡A¥Ø«eÁÙ¨S¦³¤åÄm³ø¾É¤©¥H¤ä«ù¡A¦ý¬Y¨Ç¦b￾¦Ãþ¤ÎÆFªøÃþ°Êª«¨­¤W¶i¦æªº­­¨î¼ö¶qÄá¤J¹êÅ窺µ²ªG¥i¯à¤ä«ù³o¤@µo²{¡C­­¨î¼ö¶qÄá¤J(Caloric restriction, CR)¬O¤wª¾ªº°ß¤@¯à°÷¨Ï￾¦Ãþ¤D¦ÜÆFªøÃþ°Êª«´î½w°I¦Ñ©M©µªø¹Ø©Rªº¤èªk[85,86]¡CCR¤p¹«ªº¹Ø©R©µªøªºªí«¬¤]¥i¯à»P·s³¯¥NÁªº¤U­°¤ÎUPP¬¡©Êªº¤U½Õ¦³Ãö[87,88]¡C¤Z¦¹ºØºØ³£¤ä«ù·s³¯¥NÁªº¤U­°¤]¯à¬ÛÀ³¦a¾É­P¡§©U§£³B²z¾¹¡¨ªº´î¤p³o¼Ë¤@ºØÆ[ÂI¡C¦¹¥~¡A¦³ªº¬ì¾Ç®aÁÙµo²{CR°Êª«¨ã¦³§ÜÀ³¤O©M¯e¯f©è§Ü¯à¤O¼W±j³o¤@ªí«¬[89,90]¡C¦ý¬O§_®ð¥\­×½mªÌªº©è§Ü¤O¼W±j»P¦¹¦³ÃöÁÙ¦³«Ý¶i¤@¨BÃÒ¹ê¡C­×·ÒªÌªºªx¯À³J¥Õ½è­°¸Ñ¨t²Îªº¼@¯PÅܤƻ¡©ú¦¹Åé¨t¥i¯à§@¬°¤@­Ó·s³¯¥NÁÂÅܤƪº¤À¤l·PÀ³¾¹¡CŲ©óªx¯À³J¥Õ½è­°¸Ñ¨t²Î¦b¦UºØ²Ó­M¥Í²z©M¯f²z¹Lµ{¤¤ªº­«­n©Ê¡Aªk½ü¤jªk­×·Ò©Î³\¥i§@¬°°w¹ï¦hºØ¤HÃþ¯e¯fªº´À¥NÀøªk¡C

³Ì«á¡A§Ú­Ì¤pµ²¤@¤U¥H¤Wªºµo²{¡Cºë¯«­×·Ò¥i¯à¼vÅT¤U¦C°ò¦]ªºªí¹F¡A¨ä¤¤¥]¬A³J¥Õ½è¦X¦¨»P­°¸Ñ¡A²Ó­M¥NÁ¡A²Ó­M¦º¤`¡A¥H¤Î§K¬Ì½Õ±±¡C¦¹¥~¡A§Ú­Ìªºµ²ªG¤]»¡©ú©P³ò¦å²Ó­M¥i¥H³Q¥Î¨Ó¬ã¨s°ò¦]¤ô¥­¤Wªº°ò¦]ªí¹FÅܤơC¦b³o¨ÇÅܤƤ¤¡A³Ì­È±o¤@´£ªº¬O²Ó­M­ä¹s¦º¤`°ò¦]ªº½Õ±±¡G§Ü²Ó­M­ä¹s¦º¤`°ò¦]ªº¤U½Õ±±¦³§Q©ó§K¬Ì¼W±jªº±¡ªp¤Uª¢¯g²Ó­Mªº§Ö³t¸Ñ¨M¡C³o¤@½Õ±±«D±`­«­n¡A¦]¬°¥i¥HÁקK¥Ñ©ó§K¬Ì¤O¼W±j¦Ó³y¦¨¹ï­ÓÅ骺¦Û§Ú·l¶Ë¡C»P¥NÁ²v¤U­°¦³ÃöªºÁͶդä«ùªø´Á¥H¨Óªº¬Ýªk¡A§Y­°§C¥NÁ²v¥i¯à´î½w¦Ñ¤Æ¹Lµ{©M©µªø¹Ø©R¡CUPP¨t²ÎªºÅãµÛÅܤƶi¤@¨B»¡©ú¤F³o¤@¨t²Î¦b¥Í²z©M¯f²z¤è­±ªº­«­n·N¸q¡A¤]¤ÏÀ³¤F³o¤@¨t²Î¦b¤HÃþºë¯«·NÃѤ譱¹ï°·±dªº­«­n©Ê¡C¥Ø«e¡A¬°¤F¶i¤@¨B¬ã¨s¤HÃþªººë¯«·NÃѦp¦ó¼vÅT°ò¦]ªí¹F¡A§Ú­Ì¥¿¦b¶i¦æ­×·Ò«e«áªº¹ï·Ó¡A¥H¤Î¨ä¥Lºë¯«­×·ÒªºÅܤơC§Ú­Ì§Æ±æ§Ú­Ìªº¬ã¨s¬°²{¥N¨­¤ß¬Û¤¬§@¥Î¤è­±´£¨Ñ¤@¨Ç·sªº¬ã¨sµ¦²¤©M¤è¦V¡C¡@¡@

°Ñ¦Ò¤åÄm

1. Danner DD, Snowdon DA, Friesen WV. Positive emotions in early life and longevity: findings from the nun study. J Pers Soc Psychol 2001;80(5):804-13.

2. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R. EMOTIONS, MORBIDITY, AND MORTALITY: New Perspectives from Psychoneuroimmunology. Annu Rev Psychol 2002;53:83-107.

3. Editorial. Progress and promise in research on social and cultural demensions of health: a research agenda. In: NIH, editor; 2001; NIH, Bethesda, MD 20892.

4. King MC, Wilson AC. Evolution at two levels in humans and chimpanzees. Science 1975;188(4184):107-16.

5. Paabo S. Genomics and society. The human genome and our view of ourselves. Science 2001;291(5507):1219-20.

6. Enard W, Khaitovich P, Klose J, Zollner S, Heissig F, Giavalisco P, Nieself-Struwe K, Muchmore E, Varki A, Ravid R and others. Intra- and interspecific variation in primate gene expression patterns. Science 2002;296:340-343.

7. Beecher H. The powerful placebo. JAMA 1955;159:1602-1606.

8. Shapiro AK. Placebo effects in medicine,psychotherapy, and psychoanalysis. In: Bergin A, Garfield S, editors. Handbook of psychotherapy and beharior change. New York: Wiley and Sons; 1971.

9. Benson H, Epstein MD. The placebo effect. A neglected asset in the care of patients. Jama 1975;232(12):1225-7.

10. Stefano GB, Fricchione GL, Slingsby BT, Benson H. The placebo effect and relaxation response: neural processes and their coupling to constitutive nitric oxide. Brain Res Brain Res Rev 2001;35(1):1-19.

11. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. Jama 2002;287(14):1840-7.

12. Schweiger A, Parducci A. Nocebo: the psychologic induction of pain. Pavlov J Biol Sci 1981;16(3):140-3.

13. Spiegel H. Nocebo: the power of suggestibility. Prev Med 1997;26(5 Pt 1):616-21.

14. Benson H. The nocebo effect: history and physiology. Prev Med 1997;26(5 Pt 1):612-5.

15. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. Jama 2002;287(5):622-7.

16. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001;344(21):1594-602.

17. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and Opioid Analgesia--Imaging a Shared Neuronal Network. Science 2002;7:7.

18. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001;293(5532):1164-6.

19. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002;159(1):122-9.

20. Vedantam S. Against depression, a sugar pill is hard to beat: Placebos improve mood, change brain chemistry in majority of trials of antidepressants. Washington post 2002.

21. Torrey EF, Miller J. The invisible plague: The rise of mental illness from 1750 to the present; 2001.

22. Schuster MA, Stein BD, Jaycox L, Collins RL, Marshall GN, Elliott MN, Zhou AJ, Kanouse DE, Morrison JL, Berry SH. A national survey of stress reactions after the September 11, 2001, terrorist attacks. N Engl J Med 2001;345(20):1507-12.

23. Galea S, Ahern J, Resnick H, Kilpatrick D, Bucuvalas M, Gold J, Vlahov D. Psychological sequelae of the September 11 terrorist attacks in New York City. N Engl J Med 2002;346(13):982-7.

24. Vlahov D, Galea S, Resnick H, Ahern J, Boscarino JA, Bucuvalas M, Gold J, Kilpatrick D. Increased use of cigarettes, alcohol, and marijuana among Manhattan, New York, residents after the September 11th terrorist attacks. Am J Epidemiol 2002;155(11):988-96.

25. Goodnouch A. Post-9/11 pain found to linger in young minds. New York Times 2002 May 20.

26. AP. Post-trauma stress plagues NYC kids. MSNBC 2002;http://www.msnbc.com/news/746411.asp.

27. Jacobs GD. The physiology of mind-body interactions: the stress response and the relaxation response. J Altern Complement Med 2001;7(Suppl 1):S83-92.

28. Tabor HK, Risch NJ, Myers RM. OPINION: Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet 2002;3(5):391-7.

29. Kiberstis P, Roberts L. It's Not Just the Genes. Science 2002;296(5568):685-.

30. Marx J. Unraveling the causes of diabetes. Science 2002;296(5568):686-9.

31. Marshall E. Lupus: Mysterious Disease Holds Its Secrets Tight. Science 2002;296(5568):689-691.

32. Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science 2002;296(5568):692-5.

33. Willett WC. Balancing Life-Style and Genomics Research for Disease Prevention. Science 2002;296(5568):695-698.

34. Rees J. Complex Disease and the New Clinical Sciences. Science 2002;296(5568):698-700.

35. Strohman R. Maneuvering in the Complex Path from Genotype to Phenotype. Science 2002;296(5568):701-703.

36. Editorial. Prevention remains the best medicine. Nature 2002;416(6880):416.

37. Snowdon DA, Greiner LH, Markesbery WR. Linguistic ability in early life and the neuropathology of Alzheimer's disease and cerebrovascular disease. Findings from the Nun Study. Ann N Y Acad Sci 2000;903:34-8.

38. Snowdon DA. Aging with grace: what the nun study teaches us about leading longer, healthier, and more meaningful lives. New York, New York: Bantam Books; 2001.

39. Gimbel MA. Yoga, meditation, and imagery: clinical applications. Nurse Pract Forum 1998;9(4):243-55.

40. Herrick CM, Ainsworth AD. Invest in yourself. Yoga as a self-care strategy. Nurs Forum 2000;35(2):32-6.

41. Pettinati PM. Meditation, yoga, and guided imagery. Nurs Clin North Am 2001;36(1):47-56.

42. Lewis DE. T'ai chi ch'uan. Complement Ther Nurs Midwifery 2000;6(4):204-6.

43. Chen KM, Snyder M, Krichbaum K. Clinical use of tai chi in elderly populations. Geriatr Nurs 2001;22(4):198-200.

44. Li HZ. Zhuan Falun - The Complete Teaching of Falun Gong. Gloucester: Fair Winds Press; 2001. 345 p.

45. Coker KH. Meditation and prostate cancer: integrating a mind/body intervention with traditional therapies. Semin Urol Oncol 1999;17(2):111-8.

46. Shang C. Emerging paradigms in mind-body medicine. J Altern Complement Med 2001;7(1):83-91.

47. Jones BM. Changes in cytokine production in healthy subjects practicing Guolin Qigong : a pilot study. BMC Complement Altern Med 2001;1(1):8.

48. Kaba A, Jiang PH, Chany-Fournier F, Chany C. Sarcolectin (SCL): structure and expression of the recombinant molecule. Biochimie 1999;81(7):709-15.

49. Kaiser V, Diamond G. Expression of mammalian defensin genes. J Leukoc Biol 2000;68(6):779-84.

50. van Wetering S, Sterk PJ, Rabe KF, Hiemstra PS. Defensins: key players or bystanders in infection, injury, and repair in the lung? J Allergy Clin Immunol 1999;104(6):1131-8.

51. Fellermann K, Stange EF. Defensins -- innate immunity at the epithelial frontier. Eur J Gastroenterol Hepatol 2001;13(7):771-6.

52. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14(4):778-809.

53. Shtrichman R, Samuel CE. The role of gamma interferon in antimicrobial immunity. Curr Opin Microbiol 2001;4(3):251-9.

54. Jouanguy E, Doffinger R, Dupuis S, Pallier A, Altare F, Casanova JL. IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men. Curr Opin Immunol 1999;11(3):346-51.

55. Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev 2000;11(4):321-33.

56. Horuk R, Hesselgesser J, Zhou Y, Faulds D, Halks-Miller M, Harvey S, Taub D, Samson M, Parmentier M, Rucker J and others. The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. J Biol Chem 1998;273(1):386-91.

57. Lee S, Tiffany HL, King L, Murphy PM, Golding H, Zaitseva MB. CCR8 on human thymocytes functions as a human immunodeficiency virus type 1 coreceptor. J Virol 2000;74(15):6946-52.

58. Matzinger P. An innate sense of danger. Ann N Y Acad Sci 2002;961:341-2.

59. Adams JM, Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 2001;26(1):61-6.

60. Smith JA. Neutrophils, host defense, and inflammation: a double-edged sword. J Leukoc Biol 1994;56(6):672-86.

61. Webb PR, Wang KQ, Scheel-Toellner D, Pongracz J, Salm
on M, Lord JM. Regulation of neutrophil apoptosis: a role for protein kinase C and phosphatidylinositol-3-kinase. Apoptosis 2000;5(5):451-8.

62. Ohta K, Yamashita N, Tajima M, Miyasaka T, Kawashima R, Nakano J, Arioka H, Ishii A, Horiuchi T, Miyamoto T. In vivo effects of apoptosis in asthma examined by a murine model. Int Arch Allergy Immunol 2001;124(1-3):259-61.

63. Simpson SJ, Hines PJ. Self-Discrimination, a Life and Death Issue. Science 2002;296(5566):297-.

64. Matzinger P. The Danger Model: A Renewed Sense of Self. Science 2002;296(5566):301-305.

65. Medzhitov R, Janeway CA, Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002;296(5566):298-300.

66. Akgul C, Moulding DA, Edwards SW. Molecular control of neutrophil apoptosis. FEBS Lett 2001;487(3):318-22.

67. Kasahara Y, Iwai K, Yachie A, Ohta K, Konno A, Seki H, Miyawaki T, Taniguchi N. Involvement of reactive oxygen intermediates in spontaneous and CD95 (Fas/APO-1)-mediated apoptosis of neutrophils. Blood 1997;89(5):1748-53.

68. Schneider RH, Nidich SI, Salerno JW, Sharma HM, Robinson CE, Nidich RJ, Alexander CN. Lower lipid peroxide levels in practitioners of the Transcendental Meditation program. Psychosom Med 1998;60(1):38-41.

69. Check E. Immunology: The virtue of tolerance. Nature 2002;418(6896):364-6.

70. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002;82(2):373-428.

71. Yewdell JW. Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol 2001;11(7):294-7.

72. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-79.

73. Vu PK, Sakamoto KM. Ubiquitin-mediated proteolysis and human disease. Mol Genet Metab 2000;71(1-2):261-6.

74. Ciechanover A, Schwartz AL. Ubiquitin-mediated degradation of cellular proteins in health and disease. Hepatology 2002;35(1):3-6.

75. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001;28(6):613-9.

76. Garber K. taking garbage in, tossing cancer out? Science 2002;295(5555):612-3.

77. Joazeiro CA, Weissman AM. RING finger proteins: mediators of ubiquitin ligase activity. Cell 2000;102(5):549-52.

78. Freeman H. An increase in insanity. Nature 2002;417(6885):123.

79. Jackson PK, Eldridge AG, Freed E, Furstenthal L, Hsu JY, Kaiser BK, Reimann JD. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 2000;10(10):429-39.

80. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S and others. The tripartite motif family identifies cell compartments. Embo J 2001;20(9):2140-51.

81. Coffino P. Antizyme, a mediator of ubiquitin-independent proteasomal degradation. Biochimie 2001;83(3-4):319-23.

82. Bond U, Schlesinger MJ. Ubiquitin is a heat shock protein in chicken embryo fibroblasts. Mol Cell Biol 1985;5(5):949-56.

83. Bond U, Schlesinger MJ. The chicken ubiquitin gene contains a heat shock promoter and expresses an unstable mRNA in heat-shocked cells. Mol Cell Biol 1986;6(12):4602-10.

84. Latchman DS. Heat shock proteins and cardiac protection. Cardiovasc Res 2001;51(4):637-46.

85. Lane MA, Black A, Handy A, Tilmont EM, Ingram DK, Roth GS. Caloric restriction in primates. Ann N Y Acad Sci 2001;928:287-95.

86. Roth GS, Ingram DK, Lane MA. Caloric restriction in primates and relevance to humans. Ann N Y Acad Sci 2001;928:305-15.

87. Lee CK, Klopp RG, Weindruch R, Prolla TA. Gene expression profile of aging and its retardation by caloric restriction. Science 1999;285(5432):1390-3.

88. Lee CK, Weindruch R, Prolla TA. Gene-expression profile of the ageing brain in mice. Nat Genet 2000;25(3):294-7.

89. Raffoul JJ, Guo Z, Soofi A, Heydari AR. Caloric restriction and genomic stability. J Nutr Health Aging 1999;3(2):102-10.

90. Yu BP, Chung HY. Stress resistance by caloric restriction for longevity. Ann N Y Acad Sci 2001;928:39-47.

¸} µù¡G
¤å½Z±H¥X«á¡A¤S¥X²{¤F·sªºÃÒ¾Ú´£¥Ü¨¾¿m¯À¥i¯à¤]°Ñ»P¤F·Ò¥\¤Hªº§ÜHIV§@¥Î¡C³Ìªñ¡A±iµ¥¤Hµo²{CD8ªº§Ü¯f¬r¦]¤l´N¬O¨¾¿m¯À¡]1¡A2¡A3¡^¡A¨ã¦³«Ü±jªº§Ü HIV-1ªº¬¡©Ê¡C(Zhang et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor Science 2002 Nov 1;298(5595):995-1000)

­PÁÂ:
·PÁÂ¥±³Ç¥§¨ÈMason¬ã¨s¤¤¤ß¤ý¦P¤åªº¦³¯qªº«Øij¡F·PÁ¨©°ÇÂå¾Ç°|ªºC.Wayne Smith°Q½×¡A¹ªÀy©M¤ä«ù¡F·PÁÂL.Schmidt©MC.Robinsonªº¤å¯µ¤u§@¡C·PÁ§d¬°ªºÂ½Ä¶¤u§@¡C³o¶µ¬ã¨sªº¸g¶O¨Ó¦Û¨©°ÇÂå¾Ç°|Âå¾Ç¨tªºÃ´°òª÷¡]«Ê²ú²ú¡^¡C

¡@


ºô¯¸¤ÏõX: huiyuan-editor@minghui.org  huiyuan-webteam@minghui.org
ÅwªïÂà¸ü¶Ç¾\¥»ºô©Ò¦³¤º®e¡A¦ý½Ðµù©ú¥X³B Copyright © 2002-2003 Huiyuan (Minghui)
(«Øij¥Î Internet Explorer 5, Netscape 6 ©Î§ó·sª©¥»)